Practical Pearls for the Management of Patients on U-500 Regular Human Insulin

Management of hyperglycemia in type 2 diabetes, 2015: a patient centered approach. Update to a position statement of the ADA and EASD. Diabetes Care. 2015;38:140-149.

Cochran E . U-500 insulin: when more with less yields success. Diabetes Spectrum. 2009;22(2):116-122.

Cochran E Gorden P . Use of U-500 insulin in the treatment of severe insulin resistance. Insulin. 2008;3(4):211-217.

Segal A Brunner J Burch T . Use of concentrated insulin human regular (U-500) for patients with diabetes. Am J Health Syst Pharm. 2010;67:1526-1535.

Lane W Cochran E Jackson J . High dose of insulin therapy: is it time for U-500 insulin? Endocr Pract. 2009;15(1):71-79.

Cochran E Musso C Gorden P . The use of U-500 in patients with extreme insulin resistance. Diabetes Care. 2005;28(5):1240-1244.

Jones P Idris I . The use of U-500 regular insulin in the management of patients with obesity and insulin resistance. Diabetes Obes Metab. 2013;15:882-887.

Ballani P Tran M Navar M . Clinical experience with insulin U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients. Diabetes Care. 2006;29(11):2504-2505.

Cochran E Valentine V Samaan K . Practice tips and tools for the successful use of U-500 regular human insulin. Diabetes Educ. 2014;40(2):153-165.

Concentrated Insulin Humulin R U-500. Dosing. http://www.humulinhcp.com/pages/dosing.aspx. Accessed February 1, 2015.

Collier IA Baker DM . Implementation of a pharmacist-supervised outpatient diabetes treatment clinic. Am J Health Syst Pharm. 2014;71:27-36.

Collier IA . Implementation of pharmacist-run insulin treat-to-target clinic. In: American College of Clinical Pharmacist, Ambulatory Care Survival Guide. 3rd ed. Lenexa, KS: AACP; 2013.

Crasto W Jarvis J Hackett E. Nayyar V . Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. Postgrad Med J. 2009;85:219-222.

Reutrakel S Wroblewski K Brown RL . Clinical use of U-500 regular insulin: review and meta-analysis. J Diabetes Sci Technol. 2012;6(2):412-420.

Dailey A Williams S Taneja D . Clinical efficacy and patient satisfaction with U-500 insulin use. Diabetes Res Clin Pract. 2010;88:259-264.

Product information: TOUJEO(R) subcutaneous injection, insulin glargine subcutaneous injection. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206538lbl.pdf. Accessed May 7, 2015.

Riddle MC Bolli GB Ziemen M Muehlen-Bartmer I Bizet F Home PD . New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;10;37(10):2755-2762.

Riddle MC Bolli GB Ziemen M Muehlen-Bartmer I Bizet F Home PD . New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37(10):2755-2762.

Riddle MC Bolli GB Ziemen M Muehlen-Bartmer I Bizet F Home PD . New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 3). Diabetes Care. 2014;37(10):2755-2762.

Insulin Degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomized open label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498-1507.

Gough SC Merseback H Bhargava A . Low-volume insulin Degludec 200 units/ml once daily improves glycemia control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naïve patients with type 2 diabetes. Diabetes Care. 2013;36:2536-2542.